Mangalam Drugs & Organics Ltdte (BSE: 532637) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹46 Cr, it ranks #3,839 by market cap among the 6,197 Indian listed companies on FinBizNet, and #75 of 86 in Medicinal Chemicals and Botanical Products. At ₹29.20 (as of 16 Nov 2026), the share price is 53.3% below its 52-week high of ₹62.50 and 28.1% above its 52-week low of ₹22.80. The share price is down 54.2% over one year and up 5.2% over three months.
| Current Price | ₹29.20 |
|---|---|
| Market Cap | ₹46 Cr |
| BSE Code | 532637 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -35.23% |
| Return on Assets | -5.96% |
| 52-Week Range | ₹22.80 – ₹62.50 |
| 1-Year Price Change | -54.2% |
| 3-Month Price Change | +5.2% |
| Beta (1Y) | 0.36 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.mangalamdrugs.com |
| Revenue | ₹79 Cr |
|---|---|
| Net Profit | ₹-7 Cr |
| Net Margin | -9.1% |
| EPS (Basic) | ₹-4.55 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr in Q2 FY27, up 60.3% from ₹50 Cr in Q2 FY26 and up 39.0% from ₹57 Cr in Q1 FY27. It posted a net loss of ₹7 Cr for the quarter, against a net loss of ₹7 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹50 Cr (Q2 FY26) to ₹79 Cr (Q2 FY27). The company reported a net loss in 6 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹79 Cr | −₹7 Cr | −9.1% |
| Q1 FY27 | ₹57 Cr | −₹8 Cr | −13.4% |
| Q4 FY26 | ₹67 Cr | −₹13 Cr | −19.9% |
| Q3 FY26 | ₹58 Cr | −₹10 Cr | −16.8% |
| Q2 FY26 | ₹50 Cr | −₹7 Cr | −14.8% |
| Q1 FY26 | ₹57 Cr | −₹14 Cr | −24.1% |
| Q4 FY25 | ₹73 Cr | ₹0 Cr | 0.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 35.65% of Mangalam Drugs & Organics Ltdte's shares as of Sept 2026, against 50.30% in Sept 2025 (−14.65 percentage points). Delivery averaged 76.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comp
1. Manufacturing of Bulk Drugs-This segment manufactures and sells drugs, medicines, and allied products. 2. Chemicals & Others-0 3. Segment Adjustment-This segment manufactures organic chemicals, prefumery/specialty chemicals, disperse dye intermediates, and dye products. 4. Corporate-0
1. Manufacturing of Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Mangalam Drugs & Organics Ltdte | ₹46 Cr | n/m | -35.23% | ₹79 Cr | -54.2% |
Listed by market capitalisation. Ratios are shown for context only.
Mangalam Drugs & Organics Ltdte is trading at ₹29.20, with a market capitalisation of ₹46 Cr.
Mangalam Drugs & Organics Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mangalam Drugs & Organics Ltdte has a return on equity of -35.23%.
Mangalam Drugs & Organics Ltdte is listed on the BSE under the scrip code 532637.
Mangalam Drugs & Organics Ltdte's share price is down 54.2% over one year and up 5.2% over three months. Its 52-week range is ₹22.80 to ₹62.50.
In Q2 FY27, Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr and net profit of ₹-7 Cr, with basic EPS of ₹-4.55 (consolidated, parsed from the company's exchange filing).
Mangalam Drugs & Organics Ltdte reported revenue of ₹79 Cr in Q2 FY27, up 60.3% from ₹50 Cr in Q2 FY26 and up 39.0% from ₹57 Cr in Q1 FY27.
Promoters held 35.65% of Mangalam Drugs & Organics Ltdte's shares as of Sept 2026, against 50.30% in Sept 2025 (−14.65 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.